<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760926</url>
  </required_header>
  <id_info>
    <org_study_id>ULTRA</org_study_id>
    <nct_id>NCT03760926</nct_id>
  </id_info>
  <brief_title>A Trial of the AblaCare Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility</brief_title>
  <official_title>ULTRA Study: a Feasibility, Prospective, Multicenter, Single-arm Trial of the AblaCare Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualisation in Women With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AblaCare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AblaCare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to provide preliminary evidence for the safety and&#xD;
      effectiveness of the AblaCare Kit in transvaginal ablation of ovarian tissue under ultrasound&#xD;
      visualization in women with infertility due to polycystic ovary syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) in terms of type (device/procedure related), seriousness, level of severity. Rate of occurence of intra-procedural and post-procedural adverse events, and device related complications</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful completion of a complete ovarian tissue ablation procedure, which is defined as achievement of the desired number of ablations within each ovary under ultrasound visualization.</measure>
    <time_frame>During procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ovulation following the procedure</measure>
    <time_frame>Up to 3 months after procedure</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain level using the Visual Analogue Scale (VAS - 0 : no pain - 10 : worse pain possible), record of pain medications with doses administered during procedure</measure>
    <time_frame>At procedure, 7 days, 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Usability of the AblaCare Kit</measure>
    <time_frame>During procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pain level using the Visual Analogue Scale (VAS - 0 : no pain - 10 : worse pain possible), record of pain medications with doses administered post-procedure</measure>
    <time_frame>At 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AblaCare Procedure time</measure>
    <time_frame>During procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of ovulation following the procedure</measure>
    <time_frame>Up to 6 months after procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pregnancy</measure>
    <time_frame>At 3, 6, 9 12 and 24 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>AblaCare Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AblaCare Kit</intervention_name>
    <description>The intervention consists in the realisation of the AblaCare Procedure using the AblaCare Kit, which comprises two elements: a disposable device (AblaCare Device) and a radiofrequency (RF) energy generator (AblaCare System). The AblaCare Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.</description>
    <arm_group_label>AblaCare Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Candidates for this study must meet ALL of the following criteria:&#xD;
&#xD;
        Inclusion criteria for female participants:&#xD;
&#xD;
          1. Age: ≥ 18 to ≤ 40 years&#xD;
&#xD;
          2. Diagnostic of PCOS confirmed by at least 2 of 3 Rotterdam criteria, defined as:&#xD;
&#xD;
             2.1 Infertility associated with chronic anovulation or oligomenorrhea, defined as&#xD;
             spontaneous intermenstrual periods of ≥35 days or a total of ≤9 menses per year 2.2&#xD;
             Ultrasonographic evidence of PCOS (ovarian volume ≥ 10ml and/or follicle number per&#xD;
             ovary of ≥ 20) 2.3 Evidence of hyperandrogenaemia: either clinical (hirsutism or acne)&#xD;
             or biochemical (raised serum concentration of androgens (testosterone ≥ 2.5nmol/l, or&#xD;
             FAI &gt; 4)&#xD;
&#xD;
          3. Ovarian accessibility: determined by ability to bring transvaginal ultrasound&#xD;
             transducer into close proximity to ovaries&#xD;
&#xD;
          4. Failure of first-line pharmacological treatment defined as failure to ovulate on the&#xD;
             highest dose of first line pharmacological treatment&#xD;
&#xD;
          5. At least one patent tube and normal uterine cavity as determined by sonohysterogram,&#xD;
             hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years&#xD;
&#xD;
          6. Willing to comply with protocol-specified follow-up evaluation&#xD;
&#xD;
          7. Signed informed consent&#xD;
&#xD;
             Couple inclusion criteria:&#xD;
&#xD;
          8. Normal sperm parameters based on WHO 2000 criteria (concentration⩾ 15 million/mL,&#xD;
             motility A+B ⩾ 32%, normal forms ⩾ 4%).&#xD;
&#xD;
          9. Ability to have regular intercourse during the study&#xD;
&#xD;
         10. No previous sterilization procedures (vasectomy, tubal ligation) that have been&#xD;
             reversed&#xD;
&#xD;
        Candidates will be excluded from the study if ANY of the following conditions apply:&#xD;
&#xD;
          1. Pregnant, parturient or breastfeeding women&#xD;
&#xD;
          2. Marked obesity, BMI &gt; 35&#xD;
&#xD;
          3. Marked hyperandrogenism (FAI &gt; 15)&#xD;
&#xD;
          4. Previous ovarian surgery: LOD, endometriosis surgery, ovarian cysts surgery, patients&#xD;
             with known or suspected periovarian adhesions.&#xD;
&#xD;
          5. Subject with pacemaker, defibrillator or other active implant&#xD;
&#xD;
          6. Subject is currently participating in another investigational drug or device study&#xD;
             that clinically interferes with the endpoints of this study&#xD;
&#xD;
          7. Lack of capacity to give informed consent (individuals deprived of their liberty&#xD;
             subject to a legal protection measure or who are unable to express their consent,&#xD;
             individuals under guardianship or curatorship)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32 2 535 48 56</phone>
      <email>katty.renard@stpierre-bru.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CU Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+32 2 764 78 03</phone>
      <email>patricia.vanaken@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bicetre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study coordinator</last_name>
      <phone>+330145217717</phone>
      <email>solene.fabre@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441332788664</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00441142268050</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anovulatory infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

